Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPremera Bluecross Amyloid Coverage | OpenPayer
    Ask Trek AI about this page
    ModifiedPremera BluecrossPolicy 5.01.626

    Amyloid Antibodies for the Treatment of Alzheimer's

    Customize your policy alerts

    Sign up for Premera Bluecross Policy 5.01.626 alerts

    Get alerted when Policy 5.01.626 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and prior authorization for Kisunla, Leqembi, and Leqembi Iqlik for adults with Alzheimer's disease. It defines medical-necessity criteria, documentation, dosing and quantity limits, authorization duration, investigational uses, and applicable billing codes.

    Policy Summary
    PayerPremera Bluecross
    PolicyAmyloid Antibodies for the Treatment of Alzheimer's
    Policy CodePolicy 5.01.626
    Change TypeModified
    Effective DateSeptember 1, 2026
    Last ReviewAug 11, 2026
    Next Review DateN/A
    Key ActionSubmit documentation showing that applicable drug-specific criteria are met when requesting initial authorization for Kisunla, Leqembi, or Leqembi Iqlik.
    SourceLink
    POLICY UPDATE CHANGES

    The September 2026 interim review updated the Leqembi Iqlik criteria by removing the requirement for 18 months of prior intravenous Leqembi therapy.

    The July 2026 annual review removed reference to non-formulary exception reviews and removed BCBSA Reference Policy 5.01.538 because that policy had been discontinued.

    The May 2025 annual review removed Aduhelm and HCPCS code J0172 after the manufacturer discontinued the product.

    Aduhelm (aducanumab) was removed from the policy because the manufacturer discontinued the product.

    Coverage criteria were added for Kisunla (donanemab-azbt) for treatment of Alzheimer's disease.

    Leqembi (lecanemab-irmb) coverage criteria were updated to include dosing of 10 mg/kg once every four weeks after 18 months of initial therapy.

    Leqembi Iqlik (lecanemab-irmb) criteria were updated by removing the requirement for 18 months of prior intravenous Leqembi therapy.

    The HCPCS descriptor for J0174 was updated.

    3

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Amyloid antibody products addressed
    18+Minimum age for covered treatment
    12 monthsInitial authorization period
    12 monthsBaseline brain MRI timing
    InvestigationalUnoutlined uses

    Medical Necessity and Coverage Criteria

    Initial therapy: Kisunla

    Kisunla may be considered medically necessary when ALL of the following are met.

    Kisunla eligibility

    • Clinical eligibility

      • Cognitive testing: Global Clinical Dementia Rating score of 0.5 or 1.0; CDR Memory Box score of at least 0.5; Mini-Mental Status Examination score of at least 22; or Montreal Cognitive Assessment score of at least 17.CDR 0.5 or 1.0; CDR Memory Box >=0.5; MMSE >=22; or MoCA >=17
    • Beta-amyloid confirmation: A positive amyloid PET scan or CSF biomarker testing documents abnormalities suggestive of beta-amyloid accumulation in the brain.
    • Safety and diagnostic requirements: Chart notes document ApoE ε4 status testing and discussion of ARIA-E and ARIA-H risks; a baseline brain MRI was completed within 12 months before initiation; and cognitive impairment is not due to another medical condition.Baseline MRI within 12 months

      Alternative causes include dementia with Lewy bodies, frontotemporal dementia, vascular dementia, vitamin B12 deficiency, encephalopathy, pseudodementia due to mood disorder, or untreated thyroid disease.

    • Treatment administration requirements: Kisunla is not used with another monoclonal antibody for Alzheimer's disease, is prescribed by or in consultation with a dementia specialist, and the maintenance dose is limited to 1,400 mg every 4 weeks.1,400 mg every 4 weeks

      Dementia specialists include neurologists, geriatric psychiatrists, neuropsychiatrists, and geriatricians.

    Initial therapy: Leqembi IV

    Leqembi IV may be considered medically necessary when ALL of the following are met.

    Leqembi IV eligibility

    • Clinical eligibility

      • Cognitive testing: Global Clinical Dementia Rating score of 0.5 or 1.0; CDR Memory Box score of at least 0.5; Mini-Mental Status Examination score of at least 22; or Montreal Cognitive Assessment score of at least 17.CDR 0.5 or 1.0; CDR Memory Box >=0.5; MMSE >=22; or MoCA >=17
    • Beta-amyloid confirmation: A positive amyloid PET scan or CSF biomarker testing documents abnormalities suggestive of beta-amyloid accumulation in the brain.
    • Safety and diagnostic requirements: Chart notes document ApoE ε4 status testing and discussion of ARIA-E and ARIA-H risks; a baseline brain MRI was completed within 12 months before initiation; and cognitive impairment is not due to another medical condition.

    Initial therapy: Leqembi Iqlik

    Leqembi Iqlik may be considered medically necessary when ALL of the following are met.

    Leqembi Iqlik eligibility

    • Clinical eligibility

      • Cognitive testing: Global Clinical Dementia Rating score of 0.5 or 1.0; CDR Memory Box score of at least 0.5; Mini-Mental Status Examination score of at least 22; or Montreal Cognitive Assessment score of at least 17.CDR 0.5 or 1.0; CDR Memory Box >=0.5; MMSE >=22; or MoCA >=17
    • Beta-amyloid confirmation: A positive amyloid PET scan or CSF biomarker testing documents abnormalities suggestive of beta-amyloid accumulation in the brain.
    • Safety and diagnostic requirements: Chart notes document ApoE ε4 status testing and discussion of ARIA-E and ARIA-H risks; a baseline brain MRI was completed within 12 months before initiation; and cognitive impairment is not due to another medical condition.

    Continuation therapy

    Reauthorization may be approved for up to 12 months when ALL of the following are met.

    Continuation therapy: The applicable drug-specific policy coverage criteria continue to be met; medical records demonstrate a continued positive clinical response to therapy; and a brain MRI is completed to check for radiographically observed ARIA when warranted.Up to 12 months

    Applies to Kisunla, Leqembi, and Leqembi Iqlik.

    Coverage is not available when cognitive impairment is attributable to another medical condition rather than Alzheimer’s disease. Examples include dementia with Lewy bodies, frontotemporal dementia, vascular dementia, vitamin B12 deficiency, encephalopathy, pseudodementia due to a mood disorder, or untreated thyroid disease.

    The requested amyloid antibody must not be used in combination with another monoclonal antibody for the treatment of Alzheimer’s disease. This exclusion applies to combinations involving Kisunla, Leqembi, or Leqembi Iqlik.

    This medical policy does not apply to Medicare Advantage. Coverage for Medicare Advantage members is subject to the applicable plan and coverage rules.

    Billing Codes and Clinical Parameters

    HCPCSHCPCS
    J0174Lecanemab-irmb (Leqembi), for intravenous injection, 1 mg
    J0175Injection, donanemab-azbt (Kisunla), 2 mg
    Historical and updated HCPCS codes referenced in policy historyHCPCS
    J3590Code previously used to report Aduhelm and previously used to report Leqembi; removed.
    J0172Code added to report Aduhelm and later removed because Aduhelm is no longer manufactured.
    J0174HCPCS code added to report Leqembi; descriptor updated effective April 1, 2026.
    HCPCS code referenced in policy historyHCPCS
    J0174HCPCS code to report Leqembi; descriptor updated
    Global Clinical Dementia Rating
    Qualifying score0.5 or 1.0
    AssessmentGlobal Clinical Dementia Rating (CDR)
    UseDocuments mild cognitive impairment or mild Alzheimer's disease dementia
    CDR Memory Box Score
    Qualifying scoreAt least 0.5
    AssessmentCDR Memory Box score
    Use

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Authorization Required

    Prior authorization is required before initiating Kisunla (donanemab-azbt), Leqembi (lecanemab-irmb), or Leqembi Iqlik (lecanemab-irmb). Initial authorization may be approved for up to 12 months when the applicable medical-necessity criteria are met.

    • Applies to Kisunla, Leqembi IV, and Leqembi Iqlik SC.
    Prior Authorization

    Reauthorization

    Reauthorization may be approved for up to 12 months when the drug-specific coverage criteria continue to be met, the individual demonstrates a positive clinical response, and required monitoring is documented.

    • Submit evidence of continued eligibility and clinical response.
    • Complete brain MRI to evaluate for radiographically observed amyloid-related imaging abnormalities (ARIA) when warranted.

    Clinical Background

    Alzheimer’s disease is a progressive neurodegenerative disorder characterized by cognitive and functional decline. Its principal pathologic hallmarks are amyloid plaques and tau neurofibrillary tangles.

    Amyloid positron emission tomography (PET) and cerebrospinal fluid (CSF) biomarker testing can identify beta-amyloid pathology. This policy addresses amyloid beta-directed antibody treatment for adults with Alzheimer’s disease who have mild cognitive impairment or mild Alzheimer’s disease dementia, including treatment with Kisunla and Leqembi products.

    Terms and Abbreviations

    ARIA-E
    TermARIA-E
    MeaningAmyloid-related imaging abnormalities with edema or effusion
    Policy contextA potential risk associated with amyloid antibody treatment that must be discussed
    ARIA-H
    TermARIA-H
    MeaningAmyloid-related imaging abnormalities with hemosiderin deposition
    Policy contextA potential risk associated with amyloid antibody treatment that must be discussed

    Drug-Specific Initial Therapy

    Kisunla initial therapy

    Kisunla may be considered medically necessary when ALL of the drug-specific criteria are met.

    Kisunla: The individual is aged 18 years or older, has Alzheimer's disease with mild cognitive impairment or mild Alzheimer's disease dementia documented by a qualifying cognitive test, has confirmed beta-amyloid deposition by positive amyloid PET or qualifying CSF biomarker abnormalities, has ApoE ε4 status testing and ARIA-E and ARIA-H risk counseling documented, has a baseline brain MRI completed within 12 months before initiation, does not have cognitive impairment due to another medical condition, is not receiving another Alzheimer's monoclonal antibody, receives prescribing by or consultation with a dementia specialist, and receives no more than 1,400 mg every 4 weeks.18+ years; CDR 0.5 or 1.0, CDR Memory Box >=0.5, MMSE >=22, or MoCA >=17; 1,400 mg every 4 weeks

    Dementia specialists include neurologists, geriatric psychiatrists, neuropsychiatrists, and geriatricians.

    Leqembi IV initial therapy

    Leqembi IV may be considered medically necessary when ALL of the drug-specific criteria are met.

    Reauthorization Criteria

    Reauthorization

    Reauthorization may be approved for up to 12 months when ALL of the following are met.

    Reauthorization: The drug-specific policy coverage criteria remain met; the individual continues to show a positive clinical response to therapy; and a brain MRI is completed to check for radiographically observed ARIA when warranted.Up to 12 months

    Applies to Kisunla, Leqembi, and Leqembi Iqlik.

    Leqembi Iqlik Quantity Limits

    Leqembi Iqlik 250 mg/1.25 mL Autoinjector
    Product and strengthLeqembi Iqlik 250 mg/1.25 mL autoinjector
    Quantity limit8 autoinjectors per 28 days
    Dose schedule500 mg once every week
    Leqembi Iqlik 360 mg/1.5 mL Autoinjector
    Product and strengthLeqembi Iqlik 360 mg/1.5 mL autoinjector
    Quantity limit4 autoinjectors per 28 days
    Dose schedule500 mg once every week
    Policy Summary
    PayerPremera Bluecross
    PolicyAmyloid Antibodies for the Treatment of Alzheimer's
    Policy CodePolicy 5.01.626
    Change TypeModified
    Effective DateSeptember 1, 2026
    Last ReviewAug 11, 2026
    Next Review DateN/A
    Key ActionSubmit documentation showing that applicable drug-specific criteria are met when requesting initial authorization for Kisunla, Leqembi, or Leqembi Iqlik.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaBilling Codes and Clinical ParametersAuthorization and Documentation RequirementsClinical BackgroundTerms and AbbreviationsDrug-Specific Initial TherapyReauthorization CriteriaLeqembi Iqlik Quantity Limits
    Baseline MRI within 12 months

    Alternative causes include dementia with Lewy bodies, frontotemporal dementia, vascular dementia, vitamin B12 deficiency, encephalopathy, pseudodementia due to mood disorder, or untreated thyroid disease.

  1. Treatment administration requirements: Leqembi is not used with another monoclonal antibody for Alzheimer's disease, is prescribed by or in consultation with a dementia specialist, and dosing is limited to 10 mg/kg once every two weeks for 18 months, followed after 18 months by 10 mg/kg once every 2 weeks or once every 4 weeks.10 mg/kg every 2 weeks for 18 months; thereafter every 2 or 4 weeks

    Dementia specialists include neurologists, geriatric psychiatrists, neuropsychiatrists, and geriatricians.

  2. Baseline MRI within 12 months

    Alternative causes include dementia with Lewy bodies, frontotemporal dementia, vascular dementia, vitamin B12 deficiency, encephalopathy, pseudodementia due to mood disorder, or untreated thyroid disease.

  3. Treatment administration requirements: Leqembi Iqlik is not used with another monoclonal antibody for Alzheimer's disease, is prescribed by or in consultation with a dementia specialist, the dose is limited to 500 mg once every week, and quantity is limited to 8 autoinjectors per 28 days for the 250 mg/1.25 mL autoinjector or 4 autoinjectors per 28 days for the 360 mg/1.5 mL autoinjector.500 mg once weekly; 8 or 4 autoinjectors per 28 days depending on strength

    Dementia specialists include neurologists, geriatric psychiatrists, neuropsychiatrists, and geriatricians.

  4. Documents mild cognitive impairment or mild Alzheimer's disease dementia
    Mini-Mental Status Examination
    Qualifying scoreAt least 22
    AssessmentMini-Mental Status Examination (MMSE)
    UseDocuments mild cognitive impairment or mild Alzheimer's disease dementia
    Montreal Cognitive Assessment
    Qualifying scoreAt least 17
    AssessmentMontreal Cognitive Assessment (MoCA)
    UseDocuments mild cognitive impairment or mild Alzheimer's disease dementia
    Baseline Brain MRI
    Required timingCompleted within 12 months prior to initiating treatment
    Imaging studyBaseline brain magnetic resonance imaging (MRI)
    Applies toKisunla, Leqembi IV, and Leqembi Iqlik initial therapy
    Leqembi IV Dose
    Initial dose10 mg/kg once every two weeks for 18 months
    After 18 months10 mg/kg once every 2 weeks or once every 4 weeks
    ProductLeqembi (lecanemab-irmb) IV
    Leqembi Iqlik Dose
    Dose500 mg once every week
    RouteSubcutaneous administration
    ProductLeqembi Iqlik (lecanemab-irmb)
    Kisunla Maintenance Dose
    Maintenance dose1,400 mg every 4 weeks
    ProductKisunla (donanemab-azbt)
    Administration requirementMaintenance dose is limited to 1,400 mg every 4 weeks
    Kisunla Low/Medium Tau Population
    Tau populationLow/medium tau
    Tau PET SUVR rangeAt least 1.10 and no more than 1.46
    Assessment methodTau PET imaging with flortaucipir
    Kisunla Combined Tau Population
    Tau populationCombined low/medium plus high tau population
    Tau PET SUVR thresholdGreater than 1.46
    Assessment methodTau PET imaging with flortaucipir
    Documentation Required

    Medical Records and Office Notes

    Submit medical records and office visit notes documenting that medical-necessity criteria are met for the requested therapy.

    • Office visit notes must include the diagnosis, relevant history, physical evaluation, and medication history.
    Documentation Required

    Clinical Eligibility Evidence

    Document the clinical evidence supporting eligibility for treatment with Kisunla, Leqembi, or Leqembi Iqlik.

    • Individual is aged 18 years or older and has a diagnosis of Alzheimer's disease.
    • Cognitive testing documents mild cognitive impairment or mild Alzheimer's disease dementia by at least one of the following: Global Clinical Dementia Rating (CDR) score of 0.5 or 1.0; CDR Memory Box score of at least 0.5; Mini-Mental Status Examination (MMSE) score of at least 22; or Montreal Cognitive Assessment (MoCA) score of at least 17.
    • Documented beta-amyloid deposition is demonstrated by a positive amyloid PET scan or CSF biomarker abnormalities suggestive of beta-amyloid accumulation in the brain.
    • Chart notes document ApoE ε4 status testing and discussion of potential risks, including ARIA-E and ARIA-H.
    • Baseline brain MRI was completed within 12 months before treatment initiation.
    • Documentation supports that cognitive impairment is not due to another medical condition.
    Documentation Required

    Reauthorization Documentation

    For renewal, submit records showing that the individual remains eligible under the drug-specific policy criteria and continues to respond positively to therapy.

    • Provide medical records demonstrating continued positive clinical response.
    • Document brain MRI monitoring for radiographically observed ARIA when warranted.
    • Continue to document that applicable coverage criteria remain met.
    Denial Risk

    Clinical Eligibility Not Met

    Coverage is not supported when required eligibility evidence is absent or when the individual does not meet the policy's clinical requirements.

    • Individual is younger than 18 years or does not have a diagnosis of Alzheimer's disease.
    • Cognitive testing does not indicate mild cognitive impairment or mild Alzheimer's disease dementia, or the required score documentation is absent.
    • Beta-amyloid deposition is not documented by qualifying amyloid PET or CSF biomarker evidence.
    • ApoE ε4 testing, risk discussion, or baseline brain MRI within 12 months before initiation is not documented.
    • Cognitive impairment is attributable to another condition, including dementia with Lewy bodies, frontotemporal dementia, vascular dementia, vitamin B12 deficiency, encephalopathy, pseudodementia due to a mood disorder, or untreated thyroid disease.
    Denial Risk

    Combination, Specialist, and Dosing Requirements

    The requested therapy must satisfy the policy's combination-use, specialist-prescribing, dosing, and quantity requirements.

    • Do not use Kisunla in combination with Leqembi or Leqembi Iqlik, or use Leqembi or Leqembi Iqlik in combination with another monoclonal antibody for Alzheimer's disease.
    • Treatment must be prescribed by or provided in consultation with a dementia specialist, such as a neurologist, geriatric psychiatrist, neuropsychiatrist, or geriatrician.
    • Kisunla maintenance dose: 1,400 mg every 4 weeks.
    • Leqembi IV dose: 10 mg/kg once every 2 weeks for 18 months; after 18 months, 10 mg/kg once every 2 weeks or once every 4 weeks.
    • Leqembi Iqlik dose: 500 mg once every week; quantity is limited to 8 250-mg/1.25-mL autoinjectors or 4 360-mg/1.5-mL autoinjectors per 28 days.
    Denial Risk

    Unoutlined Use

    All other uses of Kisunla, Leqembi, and Leqembi Iqlik for conditions not outlined in the policy are considered investigational and are not covered under these criteria.

    • Kisunla (donanemab-azbt)
    • Leqembi (lecanemab-irmb)
    • Leqembi Iqlik (lecanemab-irmb)
    MCI
    AbbreviationMCI
    MeaningMild cognitive impairment
    Policy contextAn early Alzheimer's disease stage represented in the treatment population
    A/T/N Biomarker Classification
    ClassificationA/T/N biomarker classification
    A, T, and NA: aggregated amyloid-beta; T: aggregated tau; N: neurodegeneration or neuronal injury
    Examples of measuresAmyloid PET or CSF Aβ for A; tau PET or phosphorylated tau for T; MRI, FDG PET, or CSF total tau for N
    CSF
    AbbreviationCSF
    MeaningCerebrospinal fluid
    Policy useMay be used for biomarker testing to document beta-amyloid accumulation
    MCI
    AbbreviationMCI
    MeaningMild cognitive impairment
    Clinical contextA cognitive stage within the Alzheimer's continuum
    MRI
    AbbreviationMRI
    MeaningMagnetic resonance imaging
    Policy useUsed for baseline imaging before treatment initiation and for evaluating neurodegeneration or neuronal injury
    PET
    AbbreviationPET
    MeaningPositron emission tomography
    Policy useUsed for amyloid or tau imaging to document relevant biomarker findings
    Leqembi IV:
    The individual is aged 18 years or older, has Alzheimer's disease with mild cognitive impairment or mild Alzheimer's disease dementia documented by a qualifying cognitive test, has confirmed beta-amyloid deposition by positive amyloid PET or qualifying CSF biomarker abnormalities, has ApoE ε4 status testing and ARIA-E and ARIA-H risk counseling documented, has a baseline brain MRI completed within 12 months before initiation, does not have cognitive impairment due to another medical condition, is not receiving another Alzheimer's monoclonal antibody, receives prescribing by or consultation with a dementia specialist, and follows the product-specific dosing schedule.
    18+ years; CDR 0.5 or 1.0, CDR Memory Box >=0.5, MMSE >=22, or MoCA >=17; 10 mg/kg every 2 weeks for 18 months, then every 2 or 4 weeks

    Dementia specialists include neurologists, geriatric psychiatrists, neuropsychiatrists, and geriatricians.

    Leqembi Iqlik initial therapy

    Leqembi Iqlik may be considered medically necessary when ALL of the drug-specific criteria are met.

    Leqembi Iqlik: The individual is aged 18 years or older, has Alzheimer's disease with mild cognitive impairment or mild Alzheimer's disease dementia documented by a qualifying cognitive test, has confirmed beta-amyloid deposition by positive amyloid PET or qualifying CSF biomarker abnormalities, has ApoE ε4 status testing and ARIA-E and ARIA-H risk counseling documented, has a baseline brain MRI completed within 12 months before initiation, does not have cognitive impairment due to another medical condition, is not receiving another Alzheimer's monoclonal antibody, receives prescribing by or consultation with a dementia specialist, receives 500 mg once every week, and meets the product-specific quantity limit.18+ years; CDR 0.5 or 1.0, CDR Memory Box >=0.5, MMSE >=22, or MoCA >=17; 500 mg once weekly; 8 or 4 autoinjectors per 28 days depending on strength

    The quantity limit is 8 autoinjectors per 28 days for the 250 mg/1.25 mL autoinjector or 4 autoinjectors per 28 days for the 360 mg/1.5 mL autoinjector. Dementia specialists include neurologists, geriatric psychiatrists, neuropsychiatrists, and geriatricians.